PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Clinical trial NCT07222215 · RECRUITING

Trial details

NCT number: NCT07222215
Sponsor: Kristina A. Fanucci
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Estrogen-receptor-positive Breast Cancer Metastatic Breast Cancer Breast Cancer Hormone Receptor Positive Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast HER2- Breast Cancer ESR1 Gene Mutation ER Wildtype Breast Neoplasms

Start date: 2026-01-16
Primary completion: 2029-12-01
Enrollment: 297

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.